Dysmenorrhea. Dysmenorrhea, unspecified
Conditions
Interventions
Intervention 1: Intervention group: For this group of patients, 0.5 milligrams Dienogest (one-quarter of a tablet produced by the Aburihan pharmaceutical factory named Dinovol) is prescribed twice a d
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: 20 to 45 years old Noticeable pain (Visual Analogue Scale>=4) in the lower abdomen or pelvic area during menstruation in the last six months With regular mensuration cycles With normal genital system physical examination and ultrasound
Exclusion criteria
Exclusion criteria: Withdrawal to participation Patients with adenomyosis, submucosal myoma, or endometriosis Patients with abnormal serum lipid profile Patients with underlying diseases or chronic pelvic pain
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dysmenorrhea. Timepoint: Four times (once before the intervention and three times after the intervention) every four weeks. Method of measurement: Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Estrogen levels. Timepoint: Before the intervention and at the end of the study. Method of measurement: Serum Estradiol (E2) measurement.;Premenstrual symptoms. Timepoint: Four times (once before the intervention and three times after the intervention) every four weeks. Method of measurement: Menstrual Distress Questionnaire.;Dienogest side effects. Timepoint: Four times (once before the intervention and three times after the intervention) every four weeks. Method of measurement: Patient interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahbod Ebrahimi
Tehran University of Medical Sciences
Outcome results
None listed